Clinical Trial: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341191) titled 'Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy' on Jan. 06.

Brief Summary: The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Mantle Cell Lymphoma

Intervention: DRUG: Zanubrutinib

assigned at enrollment

DRUG: Sonrotoclax

assigned at enrollment

BIOLOGICAL: CAR-T Cell Therapy

Standard of Care

Recruit...